Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications

• Published in: Physiological reviews Vol. 101; no. 4; pp. 1745 - 1807
• Main Authors: Ren, Jun, Wu, Ne N, Wang, Shuyi, Sowers, James R, Zhang, Yingmei
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.10.2021
• Subjects: Adipose tissue; Amino acids; Body weight; Calcium (intracellular); Calcium (mitochondrial); Calcium homeostasis; Cardiomyopathies - etiology; Cardiomyopathies - mortality; Cardiomyopathies - pathology; Cardiomyopathy; Cardiovascular disease; Cardiovascular diseases; Congestive heart failure; Coronary artery disease; COVID-19; COVID-19 - complications; COVID-19 - mortality; Epidemiology; Etiology; Fatty acids; Fibrosis; Glucose transport; Heart failure; Homeostasis; Humans; Insulin; Insulin resistance; Microvasculature; Mitochondria; Molecular modelling; Obesity; Obesity - complications; Obesity - etiology; Obesity - genetics; Overweight; Oxidative stress; Phagocytosis; Review; SARS-CoV-2; Structure-function relationships; Ventricle; cardiovascular disease; inflammation; therapy; lipotoxicity; glucotoxicity; heart; obesity
• ISSN: 0031-9333; 1522-1210
• DOI: 10.1152/physrev.00030.2020

The prevalence of heart failure is on the rise and imposes a major health threat, in part, due to the rapidly increased prevalence of overweight and obesity. To this point, epidemiological, clinical, and experimental evidence supports the existence of a unique disease entity termed "obesity cardiomyopathy," which develops independent of hypertension, coronary heart disease, and other heart diseases. Our contemporary review evaluates the evidence for this pathological condition, examines putative responsible mechanisms, and discusses therapeutic options for this disorder. Clinical findings have consolidated the presence of left ventricular dysfunction in obesity. Experimental investigations have uncovered pathophysiological changes in myocardial structure and function in genetically predisposed and diet-induced obesity. Indeed, contemporary evidence consolidates a wide array of cellular and molecular mechanisms underlying the etiology of obesity cardiomyopathy including adipose tissue dysfunction, systemic inflammation, metabolic disturbances (insulin resistance, abnormal glucose transport, spillover of free fatty acids, lipotoxicity, and amino acid derangement), altered intracellular especially mitochondrial Ca homeostasis, oxidative stress, autophagy/mitophagy defect, myocardial fibrosis, dampened coronary flow reserve, coronary microvascular disease (microangiopathy), and endothelial impairment. Given the important role of obesity in the increased risk of heart failure, especially that with preserved systolic function and the recent rises in COVID-19-associated cardiovascular mortality, this review should provide compelling evidence for the presence of obesity cardiomyopathy, independent of various comorbid conditions, underlying mechanisms, and offer new insights into potential therapeutic approaches (pharmacological and lifestyle modification) for the clinical management of obesity cardiomyopathy.